|Day Low/High||3.91 / 4.10|
|52 Wk Low/High||0.24 / 1.96|
TheStreet's biotech columnist offers his own report card on biotech stocks.
NSI-189 Shows Reversal of Radiation-induced Cognitive Deficits
NSI-189 Shows Prevention and Reversal of Diabetic Neuropathies in Mice
Dr. Karl Johe Resigns from Board of Directors; Company Announces Creation of Scientific Policy Committee with Dr. Johe as Chairman
Data Contribute to Understanding NSI-189 Mechanism of Action
These under-$10 stocks are ready to move higher from current levels. Here's how to trade them from here.
Trial Efficacy Endpoints Include Reduction in Depression and Cognition Improvement
NSI-566 Trial Data Reveals Biological Activity Across Multiple Neurodegenerative Diseases: ALS, Chronic Spinal Cord Injury, and Stroke
A much-hyped press conference reveals nothing new about Brainstorm's stem-cell therapy for ALS.